MAPT and frontotemporal dementia: In a study by Baldeiras et al. [18], the added value of another CSF Aβ-peptide (Aβ40), along with the core CSF markers T-tau, P-tau181 and Aβ42, in the discrimination between two large dementia groups of FTD (n = 107), AD (n = 107) and non-demented subjects (n = 33) was evaluated.